Light Sciences Oncology Finishes Enrollment in Pivotal Clinical Trial
Luke Timmerman11/25/08
Light Sciences Oncology, a Bellevue, WA-based developer of cancer drugs, said it has completed enrollment of 200 patients with liver tumors in a clinical trial. The goal of the study is to see whether patients live longer after they get LitX. The company’s treatment is designed to use a light-emitting diode, threaded inside a tumor, to activate a drug to kill tumors within its wavelength. If the trial reaches it goal, the company plans to ask regulators in the U.S. and Europe for marketing approval in 2009.
Luke Timmerman is the National Biotech Editor of Xconomy, and the Editor of Xconomy Seattle. E-mail him at ltimmerman@xconomy.com or follow him on Twitter at twitter.com/ldtimmerman.





SIMA SL 10IR Night Vision Video Light | Ghost Hunting Blog
12/9/08 12:25 am
[...] Light Sciences Oncology Finishes Enrollment in Pivotal Clinical Trial [...]